Akvaforsk Genetics

akvaforskgenetics.com

Akvaforsk Genetics is the leading provider of technical genetic improvement services to aquaculture industries worldwide. We have extensive experience in design, implementation and routine technical operation from more than 25 applied selective breeding programs for fish and crustacean species in Europe, Asia and Latin America. These programs cover the majority of the commercially important farmed aquaculture species, including salmonids, tilapias, marine fish and shrimp. We routinely conduct external reviews of third party broodstock management and breeding program operations.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

news image

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More

MEDICAL

MOGRIFY ANNOUNCES EXPLORATORY RESEARCH COLLABORATION WITH MRC LABORATORY OF MOLECULAR BIOLOGY

Mogrify | January 11, 2021

news image

Mogrify Limited (Mogrify®), a UK organization expecting to change the advancement of ex vivo cell therapies and pioneer the field of in vivo reconstructing treatments, and the MRC Laboratory of Molecular Biology (LMB), a top notch research lab committed to understanding significant natural cycles at the sub-atomic level, today reported an exploratory examination cooperation. The venture intends to create novel protein articulation frameworks by utilizing late advances in direct cell reconstr...

Read More

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

news image

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More

MARAVAI LIFESCIENCES EXPANDS ITS CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) CAPABILITIES AT TRILINK BIOTECHNOLOGIES

Maravai Lifesciences | August 25, 2020

news image

Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, is expanding its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTechnologies for the second time in less than a year. The expansion is expected to be completed in the first quarter of 2021 and will increase TriLink's small molecule manufacturing capacity with a focus on additional scale-up of CleanCap®, its proprietary messenger RNA (...

Read More
news image

CELL AND GENE THERAPY

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More
news image

MEDICAL

MOGRIFY ANNOUNCES EXPLORATORY RESEARCH COLLABORATION WITH MRC LABORATORY OF MOLECULAR BIOLOGY

Mogrify | January 11, 2021

Mogrify Limited (Mogrify®), a UK organization expecting to change the advancement of ex vivo cell therapies and pioneer the field of in vivo reconstructing treatments, and the MRC Laboratory of Molecular Biology (LMB), a top notch research lab committed to understanding significant natural cycles at the sub-atomic level, today reported an exploratory examination cooperation. The venture intends to create novel protein articulation frameworks by utilizing late advances in direct cell reconstr...

Read More
news image

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More
news image

MARAVAI LIFESCIENCES EXPANDS ITS CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) CAPABILITIES AT TRILINK BIOTECHNOLOGIES

Maravai Lifesciences | August 25, 2020

Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, is expanding its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTechnologies for the second time in less than a year. The expansion is expected to be completed in the first quarter of 2021 and will increase TriLink's small molecule manufacturing capacity with a focus on additional scale-up of CleanCap®, its proprietary messenger RNA (...

Read More